1. Home
  2. IMUX vs NEN Comparison

IMUX vs NEN Comparison

Compare IMUX & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.17

Market Cap

188.8M

Sector

Health Care

ML Signal

HOLD

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$58.00

Market Cap

209.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
NEN
Founded
2016
1977
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
188.8M
209.2M
IPO Year
2013
1995

Fundamental Metrics

Financial Performance
Metric
IMUX
NEN
Price
$14.17
$58.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$36.00
N/A
AVG Volume (30 Days)
232.3K
600.0
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
2.71%
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
N/A
$89,196,544.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$19.68
Revenue Growth
N/A
10.76
52 Week Low
$0.51
$56.00
52 Week High
$15.77
$74.48

Technical Indicators

Market Signals
Indicator
IMUX
NEN
Relative Strength Index (RSI) 62.56 44.85
Support Level $0.74 $56.50
Resistance Level $15.77 $60.90
Average True Range (ATR) 1.18 0.86
MACD -0.21 -0.06
Stochastic Oscillator 69.09 38.46

Price Performance

Historical Comparison
IMUX
NEN

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: